|
Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. A 2007 meta-analysis suggested when data of trials were combined, mortality was increased in people treated with cefepime compared with other β-lactam antibiotics. In response, the U.S. Food and Drug Administration performed their own meta-analysis which found no mortality difference.〔(【引用サイトリンク】title=Information for Healthcare Professionals: Cefepime (marketed as Maxipime) )〕 Cefepime was developed by Bristol-Myers Squibb and marketed beginning in 1994. It is now available as a generic drug and sold under a variety of trade names worldwide. == Medical use == Cefepime is usually reserved to treat moderate to severe nosocomial pneumonia, infections caused by multiple drug-resistant microorganisms (e.g. ''Pseudomonas aeruginosa'') and empirical treatment of febrile neutropenia. Cefepime has good activity against important pathogens including ''Pseudomonas aeruginosa'', ''Staphylococcus aureus'', and multiple drug-resistant ''Streptococcus pneumoniae''. A particular strength is its activity against Enterobacteriaceae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front-line agent when infection with Enterobacteriaceae is known or suspected. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cefepime」の詳細全文を読む スポンサード リンク
|